{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:07:43Z","timestamp":1762459663579,"version":"3.37.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41416-018-0227-2","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T10:34:03Z","timestamp":1534329243000},"page":"713-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis"],"prefix":"10.1038","volume":"119","author":[{"given":"Christoph","family":"Krisp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Pascovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas K.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Wilmott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham J.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4679-5868","authenticated-orcid":false,"given":"Mark P.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"227_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani, R. et al. Genomic classification of cutaneous melanoma. Cell 161, 1681\u20131696 (2015).","journal-title":"Cell"},{"key":"227_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175 (2017).","journal-title":"Nature"},{"key":"227_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2174\/1389450116666150204112138","volume":"16","author":"M Kunz","year":"2015","unstructured":"Kunz, M. The genetic basis of new treatment modalities in melanoma. Curr. Drug Targets 16, 233\u2013248 (2015).","journal-title":"Curr. Drug Targets"},{"key":"227_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463\u2013482 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"227_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04304","volume":"439","author":"DB Solit","year":"2006","unstructured":"Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358\u2013362 (2006).","journal-title":"Nature"},{"key":"227_CR6","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1002\/cncr.29586","volume":"121","author":"AM Menzies","year":"2015","unstructured":"Menzies, A. M. et al. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 121, 3826\u20133835 (2015).","journal-title":"Cancer"},{"key":"227_CR7","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. New Engl. J. Med. 371, 1877\u20131888 (2014).","journal-title":"New Engl. J. Med."},{"key":"227_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. New Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"New Engl. J. Med."},{"key":"227_CR9","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. New Engl. J. Med. 371, 1867\u20131876 (2014).","journal-title":"New Engl. J. Med."},{"key":"227_CR10","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long, G. V. et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 17, 1743\u20131754 (2016).","journal-title":"Lancet Oncol."},{"key":"227_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1056\/NEJMcibr1013704","volume":"364","author":"DB Solit","year":"2011","unstructured":"Solit, D. B. & Rosen, N. Resistance to BRAF inhibition in melanomas. New Engl. J. Med. 364, 772\u2013774 (2011).","journal-title":"New Engl. J. Med."},{"key":"227_CR12","doi-asserted-by":"publisher","first-page":"20411","DOI":"10.1073\/pnas.0905833106","volume":"106","author":"CM Emery","year":"2009","unstructured":"Emery, C. M. et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411\u201320416 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"227_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM Allen Van","year":"2014","unstructured":"Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94\u2013109 (2014).","journal-title":"Cancer Discov."},{"key":"227_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387\u2013390 (2011).","journal-title":"Nature"},{"key":"227_CR15","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","volume":"20","author":"H Rizos","year":"2014","unstructured":"Rizos, H. et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20, 1965\u20131977 (2014).","journal-title":"Clin. Cancer Res."},{"key":"227_CR16","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1038\/ncomms6694","volume":"5","author":"GV Long","year":"2014","unstructured":"Long, G. V. et al. Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun. 5, 5694 (2014).","journal-title":"Nat. Commun."},{"key":"227_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature12624","volume":"501","author":"CE Meacham","year":"2013","unstructured":"Meacham, C. E. & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328\u2013337 (2013).","journal-title":"Nature"},{"key":"227_CR18","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500\u2013504 (2012).","journal-title":"Nature"},{"key":"227_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505\u2013509 (2012).","journal-title":"Nature"},{"key":"227_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/35020115","volume":"406","author":"M Bittner","year":"2000","unstructured":"Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536\u2013540 (2000).","journal-title":"Nature"},{"key":"227_CR21","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1038\/jid.2011.218","volume":"131","author":"M Sensi","year":"2011","unstructured":"Sensi, M. et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J. Invest. Dermatol. 131, 2448\u20132457 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"227_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","volume":"4","author":"DJ Konieczkowski","year":"2014","unstructured":"Konieczkowski, D. J. et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 4, 816\u2013827 (2014).","journal-title":"Cancer Discov."},{"key":"227_CR23","doi-asserted-by":"publisher","first-page":"016717","DOI":"10.1074\/mcp.O111.016717","volume":"11","author":"LC Gillet","year":"2012","unstructured":"Gillet, L. C. et al. Targeted data extraction of the MS\/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteom. 11, 016717 (2012). O111.","journal-title":"Mol. Cell. Proteom."},{"key":"227_CR24","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1535-7163.MCT-11-0676","volume":"11","author":"K Dutton-Regester","year":"2012","unstructured":"Dutton-Regester, K. et al. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol. Cancer Ther. 11, 888\u2013897 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"227_CR25","doi-asserted-by":"publisher","first-page":"D1063","DOI":"10.1093\/nar\/gks1262","volume":"41","author":"J Vizcaino","year":"2013","unstructured":"Vizcaino, J. et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 41, D1063\u2013D1069 (2013).","journal-title":"Nucleic Acids Res."},{"key":"227_CR26","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1074\/mcp.M114.046425","volume":"14","author":"C Krisp","year":"2015","unstructured":"Krisp, C., Yang, H., van Soest, R. & Molloy, M. P. Online peptide fractionation using a multiphasic microfluidic liquid chromatography chip improves reproducibility and detection limits for quantitation in discovery and targeted proteomics. Mol. Cell. Proteom. 14, 1708\u20131719 (2015).","journal-title":"Mol. Cell. Proteom."},{"key":"227_CR27","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","volume":"26","author":"AA Adjei","year":"2008","unstructured":"Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139\u20132146 (2008).","journal-title":"J. Clin. Oncol."},{"key":"227_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/msb.2008.61","volume":"4","author":"V Lange","year":"2008","unstructured":"Lange, V., Picotti, P., Domon, B. & Aebersold, R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 4, 222 (2008).","journal-title":"Mol. Syst. Biol."},{"key":"227_CR29","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-12-0383","volume":"19","author":"AL Pritchard","year":"2013","unstructured":"Pritchard, A. L. & Hayward, N. K. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin. Cancer Res. 19, 2301\u20132309 (2013).","journal-title":"Clin. Cancer Res."},{"key":"227_CR30","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo, W. et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162, 1271\u20131285 (2015).","journal-title":"Cell"},{"key":"227_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2159-8290.CD-13-0631","volume":"4","author":"N Wagle","year":"2014","unstructured":"Wagle, N. et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF\/MEK inhibition. Cancer Discov. 4, 61\u201368 (2014).","journal-title":"Cancer Discov."},{"key":"227_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","volume":"19","author":"KS Hoek","year":"2006","unstructured":"Hoek, K. S. et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigm. Cell Res. 19, 290\u2013302 (2006).","journal-title":"Pigm. Cell Res."},{"key":"227_CR33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 (2010).","journal-title":"Nature"},{"key":"227_CR34","doi-asserted-by":"publisher","first-page":"e2734","DOI":"10.1371\/journal.pone.0002734","volume":"3","author":"C Wellbrock","year":"2008","unstructured":"Wellbrock, C. et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3, e2734 (2008).","journal-title":"PLoS One"},{"key":"227_CR35","first-page":"6660","volume":"51","author":"M Birch","year":"1991","unstructured":"Birch, M., Mitchell, S. & Hart, I. R. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res. 51, 6660\u20136667 (1991).","journal-title":"Cancer Res."},{"key":"227_CR36","first-page":"253","volume":"9","author":"M Korabiowska","year":"1995","unstructured":"Korabiowska, M. et al. CD-44: a marker of metastases of head and neck melanomas. in vivo 9, 253\u2013256 (1995).","journal-title":"Vivo"},{"key":"227_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1091\/mbc.7.3.383","volume":"7","author":"JR Knutson","year":"1996","unstructured":"Knutson, J. R., Iida, J., Fields, G. B. & McCarthy, J. B. CD44\/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol. Biol. Cell 7, 383\u2013396 (1996).","journal-title":"Mol. Biol. Cell"},{"key":"227_CR38","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1091\/mbc.10.10.3067","volume":"10","author":"K Maaser","year":"1999","unstructured":"Maaser, K. et al. Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol. Biol. Cell 10, 3067\u20133079 (1999).","journal-title":"Mol. Biol. Cell"},{"key":"227_CR39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/B:HIJO.0000032354.94213.69","volume":"35","author":"R Marhaba","year":"2004","unstructured":"Marhaba, R. & Zoller, M. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol. 35, 211\u2013231 (2004).","journal-title":"J. Mol. Histol."},{"key":"227_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00008390-200308000-00001","volume":"13","author":"A Gasbarri","year":"2003","unstructured":"Gasbarri, A. et al. CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. Melanoma Res. 13, 325\u2013337 (2003).","journal-title":"Melanoma Res."},{"key":"227_CR41","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1038\/sj.onc.1204435","volume":"20","author":"T Ahrens","year":"2001","unstructured":"Ahrens, T. et al. Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 20, 3399\u20133408 (2001).","journal-title":"Oncogene"},{"key":"227_CR42","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1016\/j.febslet.2014.10.027","volume":"588","author":"P Zhang","year":"2014","unstructured":"Zhang, P. et al. CD44 variant, but not standard CD44 isoforms, mediate disassembly of endothelial VE-cadherin junction on metastatic melanoma cells. FEBS Lett. 588, 4573\u20134582 (2014).","journal-title":"FEBS Lett."},{"key":"227_CR43","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1101\/gad.242602","volume":"16","author":"V Orian-Rousseau","year":"2002","unstructured":"Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P. & Ponta, H. CD44 is required for two consecutive steps in HGF\/c-Met signaling. Gene Dev. 16, 3074\u20133086 (2002).","journal-title":"Gene Dev."},{"key":"227_CR44","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1101\/gad.1430906","volume":"20","author":"C Cheng","year":"2006","unstructured":"Cheng, C., Yaffe, M. B. & Sharp, P. A. A positive feedback loop couples Ras activation and CD44 alternative splicing. Gene Dev. 20, 1715\u20131720 (2006).","journal-title":"Gene Dev."},{"key":"227_CR45","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23, 302\u2013315 (2013).","journal-title":"Cancer Cell"},{"key":"227_CR46","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","volume":"23","author":"A Roesch","year":"2013","unstructured":"Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23, 811\u2013825 (2013).","journal-title":"Cancer Cell"},{"key":"227_CR47","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1210\/en.2006-0486","volume":"147","author":"R Lupu","year":"2006","unstructured":"Lupu, R. & Menendez, J. A. Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators? Endocrinology 147, 4056\u20134066 (2006).","journal-title":"Endocrinology"},{"key":"227_CR48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/01.RES.0000160610.61306.0f","volume":"96","author":"DG Sedding","year":"2005","unstructured":"Sedding, D. G. et al. Caveolin-1 facilitates mechanosensitive protein kinase B (Akt) signaling in vitro and in vivo. Circ. Res. 96, 635\u2013642 (2005).","journal-title":"Circ. Res."},{"key":"227_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1200\/JCO.1998.16.1.35","volume":"16","author":"MJ Terol","year":"1998","unstructured":"Terol, M. J. et al. Expression of the adhesion molecule ICAM-1 in non-Hodgkin\u2019s lymphoma: relationship with tumor dissemination and prognostic importance. J. Clin. Oncol. 16, 35\u201340 (1998).","journal-title":"J. Clin. Oncol."},{"key":"227_CR50","first-page":"31","volume":"4","author":"Y Ogawa","year":"1998","unstructured":"Ogawa, Y. et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin. Cancer Res. 4, 31\u201336 (1998).","journal-title":"Clin. Cancer Res."},{"key":"227_CR51","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0959-8049(97)10033-8","volume":"34","author":"P S\u00e1nchez-Rovira","year":"1998","unstructured":"S\u00e1nchez-Rovira, P. et al. Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity. Eur. J. Cancer 34, 394\u2013398 (1998).","journal-title":"Eur. J. Cancer"},{"key":"227_CR52","first-page":"1175","volume":"6","author":"B Nakata","year":"2000","unstructured":"Nakata, B. et al. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin. Cancer Res. 6, 1175\u20131179 (2000).","journal-title":"Clin. Cancer Res."},{"key":"227_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/annonc\/mdg057","volume":"14","author":"MJ Terol","year":"2003","unstructured":"Terol, M. J. et al. Soluble intercellular adhesion molecule-1 (s-ICAM-1\/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome. Ann. Oncol. 14, 467\u2013474 (2003).","journal-title":"Ann. Oncol."},{"key":"227_CR54","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.4049\/jimmunol.174.6.3401","volume":"174","author":"SR Jenkinson","year":"2005","unstructured":"Jenkinson, S. R., Williams, N. A. & Morgan, D. J. The role of intercellular adhesion molecule-1\/LFA-1 interactions in the generation of tumor-specific CD8+ T cell responses. J. Immunol. 174, 3401\u20133407 (2005).","journal-title":"J. Immunol."},{"key":"227_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000012083","volume":"58","author":"G Anastassiou","year":"2000","unstructured":"Anastassiou, G. et al. Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: a clinicopathological study. Oncology 58, 83\u201388 (2000).","journal-title":"Oncology"},{"key":"227_CR56","doi-asserted-by":"publisher","first-page":"9854","DOI":"10.1158\/0008-5472.CAN-08-0719","volume":"68","author":"A Hama\u00ef","year":"2008","unstructured":"Hama\u00ef, A. et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K\/AKT pathway. Cancer Res. 68, 9854\u20139864 (2008).","journal-title":"Cancer Res."},{"key":"227_CR57","doi-asserted-by":"publisher","first-page":"e0144333","DOI":"10.1371\/journal.pone.0144333","volume":"10","author":"MM Linhares","year":"2015","unstructured":"Linhares, M. M. et al. Genetic and immunohistochemical expression of integrins ITGAV, ITGA6, and ITGA3 as prognostic factor for colorectal cancer: models for global and disease-free survival. PLoS ONE 10, e0144333 (2015).","journal-title":"PLoS One"},{"key":"227_CR58","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1083\/jcb.152.4.795","volume":"152","author":"AN Hume","year":"2001","unstructured":"Hume, A. N. et al. Rab27a regulates the peripheral distribution of melanosomes in melanocytes. J. Cell. Biol. 152, 795\u2013808 (2001).","journal-title":"J. Cell. Biol."},{"key":"227_CR59","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/jnci\/djp259","volume":"101","author":"KG Chen","year":"2009","unstructured":"Chen, K. G. et al. Influence of melanosome dynamics on melanoma drug sensitivity. J. Natl. Cancer Inst. 101, 1259\u20131271 (2009).","journal-title":"J. Natl. Cancer Inst."},{"key":"227_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40259-016-0208-z","volume":"31","author":"E Simeone","year":"2017","unstructured":"Simeone, E. et al. Combination treatment of patients with BRAF-mutant melanoma: a new standard of care. BioDrugs 31, 51\u201361 (2017).","journal-title":"BioDrugs"},{"key":"227_CR61","doi-asserted-by":"publisher","first-page":"e1238557","DOI":"10.1080\/2162402X.2016.1238557","volume":"5","author":"MA Deken","year":"2016","unstructured":"Deken, M. A. et al. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology 5, e1238557 (2016).","journal-title":"Oncoimmunology"},{"key":"227_CR62","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nm.3807","volume":"21","author":"T Guo","year":"2015","unstructured":"Guo, T. et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat. Med. 21, 407\u2013413 (2015).","journal-title":"Nat. Med."},{"key":"227_CR63","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl. J. Med. 367, 1694\u20131703 (2012).","journal-title":"New Engl. J. Med."},{"key":"227_CR64","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","volume":"468","author":"CM Johannessen","year":"2010","unstructured":"Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968\u2013972 (2010).","journal-title":"Nature"},{"unstructured":"Dutton-Regester K. The Identification of Therapeutic Targets in Metastatic Melanoma. - PhD thesis (Queensland University of Technology, Brisbane, QLD, 2012).","key":"227_CR65"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0227-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0227-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0227-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:07Z","timestamp":1684616587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0227-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["227"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0227-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"10 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The fresh-frozen melanoma tumor samples were obtained from the Melanoma Institute Australia Biospecimen Bank, accrued with written informed patient consent and approved by Institutional Review Board (Sydney South West Area Health Service institutional ethics review committee (Royal Prince Alfred Hospital (RPAH) Zone) Protocol No. X08-0155\/HREC 08\/RPAH\/262, No. X11-0023\/HREC 11\/RPAH\/32, and No. X07-0202\/HREC\/07\/RPAH\/30). This study was performed in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD002725 for in-vitro study and PXD007083 for human tissue specimen study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}